CONTACT

Jean-Jacques DIAZ
Group Leader

jean-jacques.diaz
@lyon.unicancer.fr

+33 (0)4 78 78 28 19

Cheney A - 4th floor
Centre Léon Bérard
28 rue Laennec
69373 Lyon Cedex 08
France
DIAZ Jean-Jacques
Team Leader
Research Director (INSERM)
Phone : 04 78 78 28 19
SAURIN Jean-Christophe
PU-PH (HCL)
Phone : 04 72 11 03 69
MERTANI Hichem

Associate Professor (UCBL)
hichem.mertani@lyon.unicancer.fr
04 78 78 28 19

CATEZ Frédéric

Research Scientist (CNRS)
frederic.catez@lyon.unicancer.fr
Téléphone : 04 26 55 68 43

MARCEL Virginie

Research Scientist  (Inserm)
virginie.marcel@lyon.unicancer.fr
Téléphone : 04 26 55 68 43

BOUVET Philippe

Professor (ENS-Lyon)
philippe.bouvet@ens-lyon.fr
Phone : +33 (0)4 69 85 60 91 

MONGELARD Fabien

Associate Professor (ENS-Lyon)
fabien.mongelard@ens-lyon.fr
Phone : +33 (0)4 69 85 60 91

DALLA VENEZIA Nicole
Research Scientist  (CNRS)
nicole.dalla-venezia@lyon.unicancer.fr

Phone : 04 26 55 67 45

VINCENT Anne
Research Scientist  (CNRS)
anne.vincent@lyon.unicancer.fr

Phone : 04 26 55 67 45

MONIER Karine

Engineer (CNRS)
karine.monier@lyon.unicancer.fr
Phone : 04 26 55 67 45

DELAGE Hélène

Assistant Engineer (CNRS)
helene.delage@lyon.unicancer.fr
Phone:  +33 (0)4 69 85 60 93

LO MONACO Piero

Post-Doctoral fellow (ANR)
piero.lomonaco@lyon.unicancer.fr
Phone : +33 (0)4 26 55 67 83

CRUZ Elizabhet
PhD Student (ENS - CONACyT)
Elizabeth.CRUZGOMEZ@lyon.unicancer.fr

Phone : 04 26 55 68 43

MALET Lucie
PhD Student (UCBL - Fondation pour la Recherche Médicale)
lucie.malet@lyon.unicancer.fr
CHALABI Mounira

Post-Doctoral fellow (ANR)
Mounira.CHALABI@lyon.unicancer.fr

GAUCHEROT Angéline
Engineer (ITMO - Inserm)
angeline.gaucherot@lyon.unicancer.fr
HULEUX Anthéa
Assistant Engineer (ANR)
anthea.huleux@lyon.unicancer.fr
MONCHIET Déborah
Assistant Engineer  (UCBL)
Deborah.MONCHIET@lyon.unicancer.fr
MOURKSI Nour El Houda
NAIT SLIMANE Sophie
PARAQINDES Hermes
Voir les objectifs et projets Voir les publications
MAIN COLLABORATIONS

International
Jonathan Yewdell – NIH, Bethesda, MD. USA
Xian Chen – University of North Carolina, NC. USA
Christine Lovly – Vanderbilt University, Nashville, TN. USA
Davide Ruggero – UCSF, San Francisco, CA. USA
Allastair Thompson and Jean-Christophe Bourdon - Ninewells Hospital & Medical School. Dundee, Scotland
Jean-Christophe Marine – VIB, Gent. Belgium
Denis Lafontaine – Université Libre de Bruxelles, Brussels. Belgium
Alberto Inga – University of Trento, Trento. Italy
Marjan Askarian-Amiri – University of Auckland, Auckland. New Zealand
Dariusz Wołowiec - Department of Hematology - Pologne
Duncan Smith - Mahidol University, Nakon Pathom. Thailand
Masoud Mehrgardi - University of Isfahan, Isfahan, Iran

National
Alain Puisieux – Institut Curie, Paris. France
Olivier NAMY - Université Paris Sud - Orsay, France
Fabrice André – Institut Gustave Roussy, Villejuif. France
Bruno Klaholtz – IGBMC, Strasbourg. France
Marat Yusupov – IGBMC, Strasbourg. France
Anne-Catherine Prats – Université de Toulouse, Toulouse. France
Fatima Mechta-Grigoriou – Institut Curie, Paris. France
Hughe de Thé – Hôpital Saint-Louis, Paris. France
Jean Soulier – Hôpital Saint-Louis, Paris. France
Raphaël Rodriguez – Institut Curie, Paris. France
Alexandre David – IGF, Montpellier. France
Julie Pannequin – IGF, Montpellier. France
Eric Rivals – LIRMM, Montpellier. France
Iouri MOTORIN – Université de Lorraine, Nancy, France
Bruno LINA – Université de Lyon, Lyon, France
Philippe Clézardin – LyOS, Lyon. France
Ambra Mari – Institut NeuroMyogène, Lyon. France

Reynald Gillet - Université de Rennes

CRCL / Centre Léon Bérard
Patrick Mehlen
Charles Dumontet 
Pierre Saintigny
Véronique Maguer-Satta
Marc Billaud and Pierre Sujobert
Marie Castet and Jean-Yves Blay
Mathieu Gabut
Pierre-Etienne Heudel
Philippe Cassier
Thomas Bachelot

Alain Viari

David Pérol

MAIN FUNDINGS 
ANR
INCa
ITMO Cancer / Plan Cancer 2014-2019
CNRS

INSERM
CLARA
La Ligue Nationale Contre le Cancer
La Ligue Contre le Cancer, comités départementaux (Rhône, Drôme, Isère, Puy-de-Dôme, Allier, Sôane-et-Loire, Loire, Haute-Loire).
Fondation ARC
Fondation Synergie Lyon Cancer

OBJECTIVES

The Ribosome Translation and Cancer Team studies the emerging role of ribosomes and ribosome heterogeneity in cancer development. We identify cancer specific alterations of the ribosomes and of the ribosome production machinery with two aims: first to better understand the process of tumor development and second to apply this knowledge to the identification of novel biomarkers, to the development of novel therapeutic strategies to treat cancer, and to understanding response to chemotherapies. Our main pathologies of interest are breast, colon, lung and pancreatic cancers.

PROJECT

Ribosome biogenesis and cancer

Our group has a long-time interest on deregulations of ribosome biogenesis that are associated with pathological conditions, and in particular with tumor development and chemo-resistance. Ribosome biogenesis is a fundamental process of cell biology since it produces the ribosomes, the ribonucleoprotein complexes driving all protein synthesis of the cell. Recently, it has emerged that all ribosomes of a cell are not identical, and that the composition of a ribosome can impact on the translation activity, including quality of protein synthesis.

It is well known that ribosome biogenesis is over-activated in cancer cells, to cope with their hyper-proliferating state. As a consequence, morphology of nucleoli (the nuclear domains hosting ribosome biogenesis) is highly modified in cancer cells, and is one of the most distinctive characteristics of tumors grade. Genetic studies in various animal models brought evidence that modification of ribosome biogenesis, and consequently of ribosomes quality, could provide a survival benefit and thus participate in cancer development. Our group showed that in human cancers, ribosome production in qualitatively altered, and in particular that the methylation pattern of ribosomal RNAs (rRNA) is modified (Belin. S et al., PLoS ONE (2009); Marcel, V. et al., Cancer Cell (2013); Erales, J. et al. PNAS (2017)).


3D structure of a ribosome from S. Cerevisae at 3, Å resolution. Large subunit : rRNA in blue, proteins in black. Small subunit : rRNA in orange, proteins in grey. © Gabriel Therizols. Rendering using Pymol. Coordinates from Ben-Shem et al. Science 2011. 

Role of 2'-O-methylation of ribosomal RNA in cancer

2'-O-methylation is the most abundant chemical modification of ribosomal RNA with 106 sites mapped in human ribosomes. Several studies including ours revealed that 2'-O-methylation contributes to the translational activity of the ribosome and impacts translation of mRNAs coding key cancer proteins (oncogenes, survival factors…). We are currently mapping 2'-O-methylation in various pathologies and cancer models to characterize 2'-O-methylation alteration and explore the potential of these alterationsin ribosome functions and as novel biomarkers. We use RiboMeth-Seq, a novel RNA-Seq based method which provides an exhaustive and quantitative mapping of 2'-O-methylation across all ribosomal RNAs (Erales, J. et al. PNAS (2017) ; Krogh, N. et al, NAR (2016)). Our current projects include studying the role of variable 2'-O-Methylation sites on ribosome function, translation regulation and cellular phenotype.

Left. 3D structure of a HeLa cell ribosome. 2'-O-methylation sites are indicated and color-coded according to their variability upon Fibrillarin methyl-transferase knockdown.
Right. 2'-O-methylation map of HeLa cell 18S rRNA obtained by RiboMethSeq.
Data and images are from Erales, J. et al. PNAS. 2017. 

Role of ribosome biogenesis master genes FBL and NCL in cancer biology

Cancer specific alterations of ribosome biogenesis are well established and contribute to both quantitative and qualitative alteration of the ribosome population in cancer cells. For instance, a wealth of data is available on RNA Pol I regulation by oncogenic and tumor suppressive pathways that coordinate ribosome biogenesis to the cell needs in healthy cells, and that abnormally increase ribosome biogenesis in cancer cells. In contrast, how downstream steps of ribosome maturation and assembly contribute to cancer specific ribosomes and to tumor phenotype has not been described yet. Fibrillarin (FBL) and Nucleolin (NCL) are two of the most important ribosome biogenesis factors and control both quantity and quality of the produced ribosome population. FBL is the 2'-O-methyltransferase of rRNAs, it is required for pre-rRNA cleavage into mature rRNAs and it stimulates RNA Pol I activity. NCL is required for RNA Pol I activity, pre-rRNA maturation and contributes to ribosome assembly. We explore the contribution and mechanistic roles of these two factors in several pathologies including breast cancer, leukemia and pancreatic cancers (Belin. S et al.,PLoS ONE (2009); Marcel, V. et al., Cancer Cell (2013), Marcel, V. et al.PLoS ONE (2017), Nguyen Van Long F, et al. Cancers, (2018), Kabirian-Dehkordi S, et al. Nanomedecine (2019)).

Ribosomal heterogeneity and chemotherapy

Our team explores the contribution of ribosome variability to the resistance and mode of action of both non-targeted and targeted therapies, in colon and lung cancer. We recently focused on 5-Fluorouracil (5-FU), the most provided anti-cancer drug worldwide. 5-FU was firstly used for its anti-proliferative activity through deleterious effects on DNA. Only recently, attention was payed to incorporation of 5-FU metabolites into cellular RNAs. While 5-FU incorporation into RNA is up to 15,000 folds higher than into DNA, consequences on RNA function remain poorly understood. We showed that 5-FU induces a translational reprogramming however by a molecular mechanism that remains to be elucidated. We recently characterized the alteration of ribosome biogenesis and ribosome composition upon 5-FU treatment and we are exploring how these modifications contribute to treated cells translation regulation and phenotype (Bash-Imam, Z. et al. Oncotarget 2017).

Our know-how. We develop and use a set of complementary technologies to describe at the molecular and cellular levels each step of ribosome biogenesis. Some are conventional biochemistry and cell biology methodologies (microscopy, reporter genes, tagged proteins…), and some are dedicated methodologies such as ribosome and nucleoli purification, polysome fractionation, or rRNA methylation analysis by RiboMethSeq. We collaborate with several teams with recognized expertise in Ribosome profiling, mass spectrometry and CryoEM analysis of ribosomes.

Openings. If you are interested to join the team, send your resume and motivation letter to Jean-Jacques Diaz (jean-jacques.diaz@lyon.unicancer.fr).

PUBLICATIONS

2020

1.     W. Sornjai, F.N. Van Long, N. Pion, A. Pasquer, JC. Saurin, V. Marcel, JJ. Diaz, H.C. Mertani, D.R. Smith. Iron and hepcidin mediate human colorectal cancer cell growth. Chemico-Biological Interactions (2020), doi: https://doi.org/10.1016/j.cbi.2020.109021.

 

2019

1.     Wei J, Kishton RJ, Angel M, Conn CS, Dalla Venezia N, Marcel V, Vincent A, Catez F, …, Diaz JJ, Qian SB, Staudt LM, Restifo NP, Yewdell JW. Ribosomal Proteins  Regulate MHC Class I Peptide Generation for Immunosurveillance. Mol Cell. 2019 doi: 10.1016/j.molcel.2018.12.020. Epub 2019 Jan 31. PubMed PMID: 30712990.

2.     Margueritat J, Virgone-Carlotta A, Monnier S, Delanoë-Ayari H, Mertani HC, Berthelot A, Martinet Q, Dagany X, Rivière C, Rieu JP, Dehoux T. High-frequency mechanical properties of tumors measured by Brillouin Light scattering. Physical Rev Letters (2019). 1:018101. doi: 10.1103

3.     Gueiderikh A, Rouvet G, Souquère-Besse S, Apcher S, Diaz JJ* and Rosselli F*. Fanconi anemia proteins are required to maintain nucleolar homeostasis. BioRxiv doi: https://doi.org/10.1101/509950. *Co-last authors

4.     Kabirian-Dehkordi S, Chalabi-Dchar M, Mertani HC, Le Guellec D, Verrier B, Diaz JJ, Mehrgardi MA and Bouvet P. AS1411-conjugated gold nanoparticles affect cell proliferation through a mechanism that seems independent of nucleolin. Nanomedicine: NBM, 21:102060 (2019)

5.     Provost A, Rousset C, Bourdon L, Mezhoud S, Reungoat E, Fourneaux C, Bresson T, Pauly M, Beard N, Possi-Tchouanlong L, Grigorov B, Bouvet P, Diaz JJ, Chamot C, Pecheur EI, Ladaviere C, Charreyre MT, Favier A, Place C, Monier K. Innovative particle standards and long-lived imaging for 2D and 3D dSTORM. Scientific Reports, 9:17967 (2019)

6.     Ussowicz M, Marcel V, Long FNV, Kazanowska B, Diaz JJ*, Wołowiec D*. Analysis of the rRNA methylation complex components in pediatric B-cell precursor acute lymphoblastic leukemia: A pilot study. Adv Clin Exp Med. 2020 Jan;29(1):107-113. doi: 10.17219/acem/112608. Co-last authors

7.     Wu N, Nguyen XN, Wang L, Appourchaux R, Zhang C, Panthu B, Gruffat H, Journo C, Alais S, Qin J, Zhang N, Tartour K, Catez F, Mahieux R, Ohlmann T, Liu M, Du B, Cimarelli A. The interferon stimulated gene 20 protein (ISG20) is an innate defense antiviral factor that discriminates self versus non-self translation. PLoS Pathog. 2019 Oct 10;15(10):e1008093. doi: 10.1371/journal.ppat.1008093.

 

2018

1.     Gachet S, El-Chaar T, Avran D, Genescà E, Catez F, Quentin S, Delord M, Therizols G, Briot D, Meunier G, Hernandez L, Pla M, Smits WK, Buijs-Gladdines JG, Van Loocke W, Menschaert G, André-Schmutz I, Taghon T, Van Vlierberghe P, Meijerink JP, Baruchel A, Dombret H, Clappier E, Diaz JJ, Gazin C, de The H, Sigaux F and Soulier J. Deletion 6q drives T-cell leukemia progression by ribosome modulation. Cancer Discovery :pii : CD-17-0831 (2018) doi: 10.1158/2159-8290.CD-17-0831. Epub 2018 Sep 28. PubMed PMID: 30266814.

2.     Nguyen Van Long F, Lardy-Cleaud A, Bray S, Chabaud S, Dubois T, Diot A, Thompson AM, Bourdon JC, Perol D, Bouvet P, Diaz JJ*, Marcel V*. The druggable nucleolin identifies breast tumours associated with poor prognosis that exhibit different biological processes. Cancers (2018) 10, 390. *Co-last authors

3.     Albaret M, Vermot-Desroches C, Paré A, Roca-Martinez J-X, Malet L, Esseily J, Gerossier L, Brière J, Pion N, Marcel V, Catez F, …, Mertani HC, Saintigny P, Diaz JJ. Externalized Keratin 8: A Target at the Interface of Microenvironment and Intracellular Signaling in Colorectal Cancer Cells. Cancers (2018) 10, 452. doi: 10.3390/cancers10110452. PubMed PMID: 30453567; PubMed Central PMCID: PMC6266717.

4.     Lisowska J, Rödel CJ, Manet S, Miroshnikova YA, Boyault C, Planus E, De Mets R, Lee HH, Destaing O, Mertani HC, Boulday G, Tournier-Lasserve E, Balland M, Abdelilah-Seyfried S, Albiges-Rizo C, Faurobert E. Cerebral Cavernous Malformation 1/2 complex controls ROCK1 and ROCK2 complementary functions for endothelial integrity. J Cell Sci (2018). doi: 10.1242/jcs.216093.

5.     Duret D, Haftek-Terreau Z, Carretier M, Berki T, Ladavière C, Monier K, Bouvet P, Marvel J, Leverrier Y, Charreyre M-T and Favier A Labeling of native proteins with fluorescent RAFT polymer probes: application to the detection of a cell surface protein using flow cytometry. Polymer Chemistry (2018), DOI: 10.1039/c7py02064c, 9,1857.

6.     Dubois J, Traversier A, Julien T, Padey B, Lina B, Bourdon JC, Marcel V, Boivin G, Rosa-Calatrava M, Terrier O. The non-structural NS1 protein of influenza viruses modulates TP53 splicing through the host factor CPSF4. J Virol. 2019. doi: 10.1128/JVI.02168-18.

 

2017

1.     Erales J,, Belin S, Ghayad SE, Garcia M, Laforêts F, Marcel V, …, Therizols G, Yusupov M, Namy O, Ohlmann T, Motorin I, Catez F, Diaz JJ. Evidence for rRNA 2'-O-methylation plasticity: control of intrinsic translational capabilities of human ribosomes. PNAS (2017) vol 114(49):12934-12939. doi: 10.1073/pnas.1707674114. Epub 2017 Nov 20. PubMed PMID: 29158377; PubMed Central PMCID: PMC5724255.

2.     Bash-Imam Z, Therizols G, Vincent A, Lafôrets F, …, Pion N, …, Saurin JC, Mertani HC, Textoris J, Auboeuf D, Catez F, Dalla Venezia N, Dutertre M*, Marcel V*, Diaz JJ*. Translational reprogramming of colorectal cancer cells induced by 5-fluorouracil through a miRNA-dependent mechanism. Oncotarget (2017) vol 8(28), 46219-46233. *Co-last authors. doi: 10.18632/oncotarget.17597.

3.     Marjanovi MP, Hurtado-Bagès S, Lassi M, Valero V, Malinverni R, Delage H, Navarro M, Corujo D, Guberovic I, Douet J, Gama-Perez P, Garcia-Roves PM, Ahel I, Ladurner AG, Yanes O, Bouvet P, Suelves M, Teperino R, Pospisilik JA, Buschbeck M. MacroH2A1.1 regulates mitochondrial respiration by limiting nuclear NAD+ consumption. Nat Struct Mol Biol 24(11):902-910 (2017) doi: 10.1038/nsmb.3481. Epub 2017 Oct 9.

4.     Benech N, Walter T, Saurin JC. Desmoid Tumors and Celecoxib with Sorafenib. N Engl J Med. 2017 Jun 29;376(26):2595-2597.

5.     Bobrowicz M, …, Berthel E, Dalla Venezia N, …, Diaz JJ, … HDAC6 inhibition up-regulates CD20 levels and increases the efficacy of anti-CD20 monoclonal antibodies. Blood 2017 Oct 5;130(14):1628-1638. doi: 10.1182/blood-2016-08-736066.

6.     Sornjai W, Lithanatudom P, Erales J, Joly P, Francina A, Hacot S, Fucharoen S, Svasti S, Diaz JJ, Mertani HC*, Smith DR*. Hypermethylation of 28S ribosomal RNA in b-thalassemia trait carriers. Int J Biol Macromol 94, 728-734 (2017) *equal senior authors.

7.     Marcel V*, Catez F*, Berger CM, Perrial E, Plesa A, Thomas X, Mattei E, Hayette S, Saintigny P, Bouvet P, Diaz JJ*, Dumontet C*. Expression profiling of ribosome biogenesis factors reveals Nucleolin as a novel potential marker to predict outcome in AML patients. PLoS One (2017) vol 12(1), e0170160. *Co-last authors. doi:10.1371/journal.pone.0170160

8.     Moraleva A, Magoulas C, Polzikov M, Hacot S, Mertani HC, Diaz J.-J. & Zatsepina O. Involvement of the specific nucleolar protein SURF6 in regulation of proliferation and ribosome biogenesis in mouse NIH/3T3 fibroblasts, Cell Cycle, 16:20, 1979-1991 (2017) doi: 10.1080/15384101.2017.1371880

9.     Lallemand F, Petitalot A, Vacher S, De Koning L, Taouis K, Lopez BS, Zinn-Justin S, Dalla Venezia N, Chemlali W, Schnitzler A, Lidereau R, Bieche I, Caputo SM. Involvement of the FOXO6 transcriptional factor in breast carcinogenesis. Oncotarget 2017 Dec 30;9(7):7464-7475. doi: 10.18632/oncotarget.23779.

10.   Douet, J., Malinverni, R., Corujo, D., Renauld, J., Sansoni, V., Marianović, M., Cantariño, N., Valero, V., Mongelard, F., Bouvet, P., Imhof, A., Thiry, M. and M. Buschbeck.. MacroH2A histone variants have a major role in nuclear organization and maintain heterochromatin architecture by tethering repeats to Lamin B1. J. Cell Sci., (2017)130(9):1570-1582

11.   Wu M, Wei W, Chen J, Cong R, Shi T, Li J, Bouvet, P., Wong J, Du JX. . Acidic domains differentially read histone H3 lysine 4 methylation status and are widely present in chromatin-associated proteins. Sci China Life Sci. (2017), 60(2):138-151.

12.   Kumar, S., Cruz, E., Chalabi M. Rong, C., Das, S., Ugrinova, I., Monier, K.  Mongelard, F. and P. Bouvet,  Integrated analysis of mRNA and miRNA expression in HeLa cells expressing low levels of nucleolin. Scientific Reports, (2017), 7(1):9017

13.   Motaghi, H., Mehrgardi, M.A and P. Bouvet.  Carbon Dots-AS1411 Aptamer Nanoconjugate for Ultrasensitive Spectrofluorometric Detection of Cancer Cells. Scientific Reports, (2017), 7(1), 10513

14.   Posavec Marjanović, M., Teperino, R., Hurtado Bagès, S., Valero, V., Malinverni, R., Delage, H.., Navarro, M., Gamma, P., Garcia-Roves, P., Yanes, O., Bouvet, P., Suelves, M., Pospisilik, JA, and M. Buschbeck.  A splicing switch of the histone variant macroH2A1 couples the chromatin state to energy metabolism. Nat. Struct. Molec. Biol, (2017) 11, 902-910.

2016

1.     Terrier O, Carron C, De Chassey B, Dubois J, Traversier A, Julien T, Cartet G, Proust A, Hacot S, Ressnikoff D, Lotteau V, Lina B, Diaz JJ, Moulès V, and Rosa-Calatrava M. Nucleolin interacts with influenza A nucleoprotein and contributes to viral ribonucleoprotein complexes nuclear trafficking and efficient influenza viral replication. Sci Rep 6, 29006 (2016).

2.     Vouyovitch CM, Perry JK, Liu DX, Bezin L, Vilain E, Diaz JJ, Lobie PE, Mertani HC. WNT4 mediates the autocrine effects of growth hormone in mammary carcinoma cells. Endoc Relat Cancer 23, 571-585 (2016).

3.     Salvetti, A., Coute, Y., Epstein, A., Arata, L., Kraut, A., Navratil, V., Bouvet, P. and A. Greco. Functions of nuclear nucleolin through global proteomics and interactomic approaches. J of Proteomic Research, (2016), 15, 1659-1669.

4.     Gaume X., Place C., Delage H., Mongelard F., Monnier K*. and P. Bouvet*.  Nucleolin contributes to microtubule stabilization. Plos One, (2016), 11(6):e0157534. *Co-last authors

5.     Lacour W, Adjili S, Blaising J, Favier A, Monier K, Mezhoud S, Place C, Ladavière C, Pecheur EI, Charreyre MT. Far-red fluorescent lipid-polymer probes for an efficient labeling of enveloped viruses. Advanced Healthcare materials (2016), DOI 10.1002, April.26.

6.     Swaminathan, A., Delage, H., Chatterjee, S,  Dutron, L., Cassel, R., Martinez, N., Cosquer, B., Kumari, S., Mongelard, F., Lannes, B., Cassel, J.C., Boutillier, A.L., Bouvet, P., and T.K. Kundu. . Transcriptional Positive Coactivator 4 (PC4) is critical for brain plasticity. J. Biol Chem, (2016), 291(39):20303-14.

7.     Gilles, Maione , Cossutta , Carpentier , Caruana , Di Maria ,Houppe , Destouches , Shchors , Prochasson , Mongelard , Lamba , Bardelli , Bouvet , Couvelard , Courty , Giraudo. Nucleolin targeting impairs the progression of pancreatic cancer and promotes the normalization of tumor vasculature. Cancer Research, (2016), 76(24):7181-7193.

8.     Virgone-Carlotta A, Lemasson M, Mertani HC, Diaz J-J, Monnier S, Dehoux T, Delanoë-Ayaria H, Rivière C* and Rieu JP*. Indepth phenotypic characterization of multicellular tumor spheroids: Effects of 5-Fluorouracil. PLoS ONE 12(11): e0188100 (2017). doi.org/10.1371/ journal.pone.0188100

9.     Granzotto A, …, Vincent A, Dalla Venezia N, …. Influence of the nucleoshuttling of the ATM protein in the healthy tissues response to radiation therapy: toward a molecular classification of human radiosensitivity. Int. J. Radiat. Oncol. Biol. Phys. 2016 Mar 1;94(3):450-60. doi: 10.1016/j.ijrobp.2015.11.013.

10.   Vincent A, Berthel E, Dacheux E, Magnard C, Dalla Venezia N. BRCA1 affects Protein Phosphatase 6 signalling through its interaction with ANKRD28. Biochem. J. 2016 Apr 1;473(7):949-60. doi: 10.1042/BJ20150797.

2015

1.     Adjili A, Favier A, Fargier G, Thomas A, Massin J, Monier K., Favard C, Vanbelle C, Andraud C, Muriaux D, Charreyre MT Biocompatible photoresistant far red emitting fluorescent probes with near-infrared two-photon absorption for labeling living cells, Biomaterials (2015) doi: 10.1016/j.biomaterials.2014.12.026, Apr;46:70-81.

2.     Gaume, X., Tassin, A.M., Ugrinova, I., Mongelard, F., Monier, K*. and P. Bouvet*. Centrosomal nucleolin is required for microtubule network organization. Cell Cycle, 2015, 14(6):902-19. *Co-last authors

3.     De Laplanche E, Boudria A, Dacheux E, Vincent A, Gadot N, Assade F, Le Corf K, Leroy X, Mège-Lechevalier F, Eymin B, Dalla Venezia N, Simonnet H. Low glucose microenvironment of normal kidney cells stabilizes a subset of messengers involved in angiogenesis. Physiol. Rep. 2015 Jan 19;3(1). pii: e12253. doi: 10.14814/phy2.12253.

4.     Joly MO, Attignon V, Saurin JC, Desseigne F, Leroux D, Martin-Denavit T, Giraud S, Bonnet-Dupeyron MN, Faivre L, Auclair J, Grand-Masson C, Audoynaud C, Wang Q. Somatic MMR Gene Mutations as a Cause for MSI-H Sebaceous Neoplasms in Muir-Torre Syndrome-Like Patients. Hum Mutat. 2015 Mar;36(3):292-5.

5.     Marchalot J, Chateaux JF, Faivre M, Mertani HC, Ferrigno R, Deman AL. Dielectrophoretic capture of low abundance cell population using thick electrodes. Biomicrofluidics. (2015) ;9:054104.

 

2014

1.     Cong, R., Das, S., Douet, J., Wong, J., Buschbeck, M., Mongelard, F. and P. Bouvet . macroH2A1 histone variant represses rDNA transcription. Nucleic Acids Research, 2014, 42, 181-192.

2.     Sagne C, Marcel V, Bota M, Martel-Planche G, …, Perriaud L, Boniol M, Vagner S, Cox DG, Chan CS, Mergny JL, Olivier M, Ashton-Prolla P, Hall J, Hainaut P, Achatz MI. Age at cancer onset in germline TP53 mutation carriers: association with polymorphisms in predicted G-quadruplex structures. Carcinogenesis (2014) vol 35(4), 807-815.

3.     Couderc C, Bollard J, Couté Y, Massoma P, Poncet G, Lepinasse F, Hervieu V, Gadot N, Sanchez JC,Scoazec JY, Diaz JJ, Roche C. Mechanisms of local invasion in enteroendocrine tumors: Identification of novel candidate cytoskeleton-associated proteins in an experimental mouse model by a proteomic approach and validation in human tumors. Mol Cell Endocrinol pii: S0303-7207(14)00284-6 (2014).

4.     Catez F., Rousseau A., Labetoulle M., Lomonte P. Detection of persistent DNA virus genome and transcripts in neuronal tissue sections by fluorescent in situ hybridization combined to immuno-staining. (2014). J Vis Exp. Jan 23;(83).

5.     Perriaud L, Marcel V, Sagne C, Favaudon V, Guédin A, De Rache A, Guetta C, Hamon F, Teulade-Fichou MP, Hainaut P, Mergny JL, Hall J. Impact of G-quadruplex structures and intronic polymorphisms rs17878362 and rs1642785 on basal and ionizing radiation-induced expression of alternative p53 transcripts. Carcinogenesis (2014) vol 35(12),2706-2715.

6.     Marcel V, Fernandes K, Terrier O, Lane DP, Bourdon JC. Modulation of p53b and p53g expression by regulating the alternative splicing of TP53 gene modifies cellular response. Cell Death Diff (2014) vol 21(9), 1377-1387.

7.     Durut, N., Abou-Ellail, M., Pontvianne, F., Das, S., Kojima, H., Ukai, S., DeBures, A., Comella, P., Echeverria, M., Bouvet, P., Nakamura, K., J. Sáez-Vásquez.  A duplicated NUCLEOLIN gene with antagonistic activity in Arabidopsis is required for methylation and organization of silent 45S rRNA genes.  The Plant Cell, 2014,26,1330-44.

8.     Shandilya J, Senapati P, Hans F, Menoni H, Bouvet P, Dimitrov S, Angelov D, Kundu TK. Centromeric histone variant CENP-A represses acetylation dependent chromatin transcription that is relieved by histone chaperone NPM1. J Biochem, 2014, 156(4):221-7.

 

CENTRE DE RECHERCHE EN CANCEROLOGIE DE LYON (CRCL)
UMR INSERM 1052 CNRS 5286 - CENTRE LEON BERARD
Copyright 2011. CRCL
SUIVEZ LES ACTUALITES
DU CRCL SUR TWITTER :